Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 15 of 15

TitleReference numberPublishedLast updated
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraineHTG643
YAG laser vitreolysis for symptomatic vitreous floatersHTG644
Osteoarthritis in over 16s: diagnosis and managementNG226
Osteoarthritis in over 16sQS87
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
O2matic PRO 100 for optimising oxygen treatment in respiratory conditionsMIB308
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642
Signatera for detecting molecular residual disease from solid tumour cancersMIB307

Results per page

  1. 10
  2. 25
  3. 50
  4. All